Document is current
Any future updates will be listed below
-
Authors
Borremans, Kristien https://orcid.org/0000-0001-7047-1543
Pabba, Anirudh
Zels, Gitte
Mahdami, Amena
Carette, Camille https://orcid.org/0009-0006-7921-212X
Maetens, Marion
Van Baelen, Karen
Van Cauwenberge, Josephine https://orcid.org/0000-0001-9802-186X
Nguyen, Ha Linh https://orcid.org/0000-0002-2538-7657
Izci, Hava
Leduc, Sophia
Hatse, Sigrid https://orcid.org/0000-0002-6764-2628
Nysen, Madita
Boeckx, Bram https://orcid.org/0000-0002-0296-6680
Vanderheyden, Evy
Brussel, Thomas Van
Derouane, Françoise https://orcid.org/0000-0002-0199-1366
Punie, Kevin
Van Den Bogaert, Wouter https://orcid.org/0000-0002-5803-3409
Vermeulen, Peter
Biganzoli, Elia https://orcid.org/0000-0003-1202-5873
Lambrechts, Diether https://orcid.org/0000-0002-3429-302X
Neven, Patrick https://orcid.org/0000-0002-1434-9460
Wildiers, Hans https://orcid.org/0000-0001-8990-7837
Floris, Giuseppe https://orcid.org/0000-0003-2391-5425
Richard, François https://orcid.org/0000-0003-4353-3619
Desmedt, Christine https://orcid.org/0000-0002-5223-5579
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 27 November 2025
First Online: 26 December 2025
Competing interests
: F.D. received speaker fees and/or honoraria for consultancy or advisory functions from Novartis and Gilead Sciences. K.P. received speaker fees and/or honoraria for consultancy or advisory functions from AstraZeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead Sciences, Medscape, MSD, Mundi Pharma, Need Inc., Novartis, Pfizer, Hoffmann/La Roche, Sanofi, and Seagen. H.W.: his institution received financial compensation on his behalf for advisory boards, lecture fees, and/or consultancy fees from Daiichi Sankyo, Gilead, Lilly, Pfizer, Novartis, PSI, Augustine Therapeutics, AstraZeneca, Roche, Agendia, Immutep, Seagen. He received travel support from Daiichi Sankyo. The remaining authors declare no potential conflicts of interest.
